These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 25184245)

  • 1. Probing the activity modification space of the cysteine peptidase cathepsin K with novel allosteric modifiers.
    Novinec M; Lenarčič B; Baici A
    PLoS One; 2014; 9(9):e106642. PubMed ID: 25184245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel allosteric mechanism in the cysteine peptidase cathepsin K discovered by computational methods.
    Novinec M; Korenč M; Caflisch A; Ranganathan R; Lenarčič B; Baici A
    Nat Commun; 2014; 5():3287. PubMed ID: 24518821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conformational flexibility and allosteric regulation of cathepsin K.
    Novinec M; Kovacic L; Lenarcic B; Baici A
    Biochem J; 2010 Jul; 429(2):379-89. PubMed ID: 20450492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational investigation of conformational variability and allostery in cathepsin K and other related peptidases.
    Novinec M
    PLoS One; 2017; 12(8):e0182387. PubMed ID: 28771551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An allosteric site enables fine-tuning of cathepsin K by diverse effectors.
    Novinec M; Rebernik M; Lenarčič B
    FEBS Lett; 2016 Dec; 590(24):4507-4518. PubMed ID: 27859061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cathepsin K: a unique collagenolytic cysteine peptidase.
    Novinec M; Lenarčič B
    Biol Chem; 2013 Sep; 394(9):1163-79. PubMed ID: 23629523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and kinetic characterization of hyperbolic inhibitors of human cathepsins K and S based on a succinimide scaffold.
    Goričan T; Ciber L; Petek N; Svete J; Novinec M
    Bioorg Chem; 2021 Oct; 115():105213. PubMed ID: 34364050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cathepsin S cannibalism of cathepsin K as a mechanism to reduce type I collagen degradation.
    Barry ZT; Platt MO
    J Biol Chem; 2012 Aug; 287(33):27723-30. PubMed ID: 22730330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clusterin is a specific stabilizer and liberator of extracellular cathepsin K.
    Novinec M; Lenarčič B; Baici A
    FEBS Lett; 2012 Apr; 586(7):1062-6. PubMed ID: 22569264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of potential allosteric binding sites in cathepsin K based on intramolecular communication.
    Rocha GV; Bastos LS; Costa MGS
    Proteins; 2020 Dec; 88(12):1675-1687. PubMed ID: 32683717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of Inhibitory Activity by Combining Allosteric Inhibitors Putatively Binding to Different Allosteric Sites on Cathepsin K.
    Sato S; Yamamoto K; Ito M; Nishino K; Otsuka T; Irie K; Nagao M
    Molecules; 2023 May; 28(10):. PubMed ID: 37241936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cathepsin K inhibitors for osteoporosis and potential off-target effects.
    Brömme D; Lecaille F
    Expert Opin Investig Drugs; 2009 May; 18(5):585-600. PubMed ID: 19388876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of cathepsin S detection using a designed FRET peptide based on putative natural substrates.
    Oliveira M; Torquato RJ; Alves MF; Juliano MA; Brömme D; Barros NM; Carmona AK
    Peptides; 2010 Apr; 31(4):562-7. PubMed ID: 20045715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptidomimetic inhibitors of cathepsin K.
    Black WC
    Curr Top Med Chem; 2010; 10(7):745-51. PubMed ID: 20337585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural basis of collagen fiber degradation by cathepsin K.
    Aguda AH; Panwar P; Du X; Nguyen NT; Brayer GD; Brömme D
    Proc Natl Acad Sci U S A; 2014 Dec; 111(49):17474-9. PubMed ID: 25422423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural requirements for the collagenase and elastase activity of cathepsin K and its selective inhibition by an exosite inhibitor.
    Sharma V; Panwar P; O'Donoghue AJ; Cui H; Guido RV; Craik CS; Brömme D
    Biochem J; 2015 Jan; 465(1):163-73. PubMed ID: 25279554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of substrate-specific inhibitors of cathepsin K through high-throughput screening.
    Law S; Du X; Panwar P; Honson NS; Pfeifer T; Roberge M; Brömme D
    Biochem J; 2019 Feb; 476(3):499-512. PubMed ID: 30622151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interventional value of total flavonoids from Rhizoma Drynariae on Cathepsin K, a potential target of osteoporosis.
    Shi XL; Liu K; Wu LG
    Chin J Integr Med; 2011 Jul; 17(7):556-60. PubMed ID: 21725884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cathepsin K and matrix metalloproteases activity in the bone tissue of OXYS rats with developing osteoporosis].
    Venediktova AA; Falameeva OV; Kolosova NG; Sadovoĭ MA; Korolenko TA
    Biomed Khim; 2010; 56(2):274-82. PubMed ID: 21341515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis.
    Costa AG; Cusano NE; Silva BC; Cremers S; Bilezikian JP
    Nat Rev Rheumatol; 2011 Jun; 7(8):447-56. PubMed ID: 21670768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.